Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 1 (2004), Issue 3 (October)

1. Lipoteichoic acid derived from Enterococcus faecalis modulates the functional characteristics of both normal peripheral blood leukocytes and native human acute myelogenous leukemia blasts.
   Eur J Haematol, 73(5): 340-50. [Abstract] [Full-text]
2. Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study.
   Blood, 104(8): 2467-74. [Abstract] [Full-text]
3. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
   Proc Natl Acad Sci U S A, 101(40): 14479-84. [Abstract] [Full-text]
4. MLL/GRAF fusion in an infant acute monocytic leukemia (AML M5b) with a cytogenetically cryptic ins(5;11)(q31;q23q23).
   Genes Chromosomes Cancer, 41(4): 400-4. [Abstract] [Full-text]
5. Complex cytogenetics in a case of probably work related MDS/AML.
   Leuk Res, 28(12): 1357-61. [Abstract] [Full-text]
6. Histopathologic verification of acute leukemia (AL) in a cohort of 463 post-Chernobyl patients from Belarus, Russia and Ukraine.
   Leuk Res, 28(12): 1273-80. [Abstract] [Full-text]
7. Malignant hematopoietic cell lines: in vitro models for the study of erythroleukemia.
   Leuk Res, 28(12): 1243-51. [Abstract] [Full-text]
8. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
   Ann Hematol, 83(11): 696-703. [Abstract] [Full-text]
9. Early plasmacytoid dendritic cell leukemia/lymphoma coexpressing myeloid antigenes.
   Ann Hematol, 83(11): 716-21. [Abstract] [Full-text]
10. Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia.
    Bone Marrow Transplant, 34(9): 799-806. [Abstract] [Full-text]
11. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.
    Cancer Res, 64(20): 7399-404. [Abstract] [Full-text]
12. Birth weight and risk for childhood leukemia in Denmark, Sweden, Norway, and Iceland.
    J Natl Cancer Inst, 96(20): 1549-56. [Abstract] [Full-text]
13. Immunobiologic therapies for myelodysplastic syndrome.
    Best Pract Res Clin Haematol, 17(4): 653-61. [Abstract] [Full-text]
14. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome.
    Best Pract Res Clin Haematol, 17(4): 641-51. [Abstract] [Full-text]
15. Modulation of angiogenesis in patients with myelodysplastic syndrome.
    Best Pract Res Clin Haematol, 17(4): 623-39. [Abstract] [Full-text]
16. Inhibitors of signaling in myelodysplastic syndrome.
    Best Pract Res Clin Haematol, 17(4): 613-22. [Abstract] [Full-text]
17. Transplant strategies for myelodysplastic syndrome.
    Best Pract Res Clin Haematol, 17(4): 559-72. [Abstract] [Full-text]
18. Pathobiology, classification, and diagnosis of myelodysplastic syndrome.
    Best Pract Res Clin Haematol, 17(4): 543-57. [Abstract] [Full-text]
19. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice.
    Proc Natl Acad Sci U S A, 101(42): 15184-9. [Abstract] [Full-text]
20. Possible trimethoprim/sulfamethoxazole-induced aseptic meningitis.
    Ann Pharmacother, 38(11): 1863-7. [Abstract] [Full-text]
21. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia.
    J Clin Pharmacol, 44(11): 1309-22. [Abstract] [Full-text]
22. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.
    Blood, 104(9): 2867-72. [Abstract] [Full-text]
23. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes.
    Blood, 104(9): 2646-54. [Abstract] [Full-text]
24. Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity.
    Clin Cancer Res, 10(20): 7043-52. [Abstract] [Full-text]
25. Proteomic analysis of human acute leukemia cells: insight into their classification.
    Clin Cancer Res, 10(20): 6887-96. [Abstract] [Full-text]
26. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
    Clin Cancer Res, 10(20): 6830-9. [Abstract] [Full-text]
27. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
    Am J Hematol, 77(3): 209-14. [Abstract] [Full-text]
28. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia.
    Am J Hematol, 77(3): 233-40. [Abstract] [Full-text]
29. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.
    Clin Chem, 50(11): 2059-68. [Abstract] [Full-text]
30. PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.
    Leukemia, 18(11): 1831-4. [Abstract] [Full-text]
31. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.
    Leukemia, 18(11): 1789-97. [Abstract] [Full-text]
32. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
    Leukemia, 18(11): 1798-803. [Abstract] [Full-text]
33. ETO/MTG8 is an inhibitor of C/EBPbeta activity and a regulator of early adipogenesis.
    Mol Cell Biol, 24(22): 9863-72. [Abstract] [Full-text]
34. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
    J Clin Oncol, 22(21): 4384-93. [Abstract] [Full-text]
35. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
    J Clin Oncol, 22(21): 4290-301. [Abstract] [Full-text]
36. Survivin expression in acute leukemias and myelodysplastic syndromes.
    Leuk Lymphoma, 45(11): 2229-37. [Abstract] [Full-text]
37. Comparison of two functional flow cytometric assays to assess P-gp activity in acute leukemia.
    Leuk Lymphoma, 45(11): 2221-8. [Abstract] [Full-text]
38. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
    Cytometry B Clin Cytom, 62(1): 25-38. [Abstract] [Full-text]

© 2004-2008 Acute Myeloid Leukemia Research Today. All Rights Reserved.